Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Go back to Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule| (NASDAQ: HELP) | Delayed: 12.39 +0.17 (1.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.22 | 52 Week High | $ | |||
| Open | $12.20 | 52 Week Low | $ | |||
| Day High | $12.73 | P/E | N/A | |||
| Day Low | $11.92 | EPS | $ | |||
| Volume | 1,634,638 | |||||
